6 results
Outpatient Treatment of with Community-Acquired Pneumonia (CAP)
No comorbidities or risk factors for MRSA or Pseudomonas aeruginosa:
Outpatient Treatment ... fluoroquinolone #IDSA ... #Pneumonia #Antibiotics ... #Management #Guidelines ... #pharmacology
IDSA Recommendations for Treating Mucosal Candidiasis in HIV-AIDS
Oropharyngeal Candidiasis: Initial Episodes (Duration of Therapy: 7–14 days)
Preferred
IDSA Recommendations ... antifungals are required ... #Prevention #Treatment ... #management #opportunistic ... infections #HIVAIDS #pharmacology
IDSA Recommendations for Preventing and Treating Varicella Zoster Virus (VZV) Infections in HIV-AIDS
Pre-Exposure Prevention of VZV
IDSA Recommendations ... #Zoster #VZV #IDSA ... #Prevention #Treatment ... #management #opportunistic ... infections #HIVAIDS #pharmacology
IDSA Recommendations for Preventing and Managing Microsporidiosis in HIV-AIDS
Preventing Chronic Microsporidiosis:
 • Because chronic microsporidiosis occurs
IDSA Recommendations ... Microsporidiosis #IDSA ... #Prevention #Treatment ... #management #opportunistic ... infections #HIVAIDS #pharmacology
IDSA Recommendations for Treating Herpes Simplex Virus (HSV) Infections in HIV-AIDS
Treating Orolabial Lesions (Duration: 5–10 days)
IDSA Recommendations ... Herpes Simplex Virus ... #Prevention #Treatment ... #management #opportunistic ... infections #HIVAIDS #pharmacology
IDSA Recommendations for Treating Coccidiodomycosis in HIV-AIDS
Treating Mild Infections (Such As Focal Pneumonia or asymptomatic patients
IDSA Recommendations ... with positive serology ... #Prevention #Treatment ... #management #opportunistic ... infections #HIVAIDS #pharmacology